Related references
Note: Only part of the references are listed.Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge
Huan Ma et al.
SCIENCE CHINA-LIFE SCIENCES (2021)
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Michael Letko et al.
NATURE MICROBIOLOGY (2020)
An Infectious cDNA Clone of SARS-CoV-2
Xuping Xie et al.
CELL HOST & MICROBE (2020)
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Chenguang Shen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Kai Duan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Shibo Jiang et al.
TRENDS IN IMMUNOLOGY (2020)
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays
Katharine H. D. Crawford et al.
VIRUSES-BASEL (2020)
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Xiuyuan Ou et al.
NATURE COMMUNICATIONS (2020)
Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody
Dora Pinto et al.
NATURE (2020)
Convalescent Plasma Therapy for COVID-19: State of the Art
Daniele Focosi et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively
Fabrizio Bonelli et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2020)
Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
A. J. Jaaskelainen et al.
JOURNAL OF CLINICAL VIROLOGY (2020)
Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test
Silvia Meschi et al.
JOURNAL OF CLINICAL VIROLOGY (2020)
Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays
Lisa Weidner et al.
JOURNAL OF CLINICAL VIROLOGY (2020)
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Fabian Schmidt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Davide F. Robbiani et al.
NATURE (2020)
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
Antonio E. Muruato et al.
NATURE COMMUNICATIONS (2020)
Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2
Marina Johnson et al.
JOURNAL OF CLINICAL VIROLOGY (2020)
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients
Nisreen M. A. Okba et al.
EMERGING INFECTIOUS DISEASES (2020)
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Mehul S. Suthar et al.
CELL REPORTS MEDICINE (2020)
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Jianhui Nie et al.
EMERGING MICROBES & INFECTIONS (2020)
Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis
Francesca Ferrara et al.
METHODS AND PROTOCOLS (2018)
A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
Gabriel J. Robbie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome
W Liu et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63
KH Chan et al.
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY (2005)
A human SARS-CoV neutralizing antibody against epitope on S2 protein
JZ Duan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein
XF Zhong et al.
JOURNAL OF VIROLOGY (2005)
Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes
NJ Temperton et al.
EMERGING INFECTIOUS DISEASES (2005)
Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: Implications for the development of vaccines and antiviral agents
CT Keng et al.
JOURNAL OF VIROLOGY (2005)
Share Paper
